Cantargia presents new data at SITC 2022 supporting nadunolimab's promising antitumor clinical efficacy

LUND, Sweden, Nov. 7, 2022 /PRNewswire/ -- Cantargia (Cantargia AB; NASDAQ Stockholm: CANTA) today reported...

Related Keywords

Boston ,Massachusetts ,United States ,Sweden ,Stockholm ,Camilla Rydberg Millrud ,Prnewswire Cantargia ,Pancreatic Cancer Action Network Pan ,Nasdaq ,Pancreatic Cancer Action Network ,Immune Monitoring ,Novel Technologiesabstract ,Camilla Rydberg ,Nasdaq Stockholm ,